Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (August 2017)
32 slides from Medical Developments International's investor presentation, Aug 18, 2017
Slide 1: Medical Developments International August 2017
For personal use only Medical Developments International August 2017
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, For personal use only ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discu
Slide 3: Vision
Vision For personal use only Medical Developments International (MVP) is a leading Emergency Medicine Company. Our aim is to: 1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader globally. 2. Provide
Slide 4: Penthrox
For personal use only Penthrox® 4
Slide 5: Penthrox UK and Ireland update
Penthrox® UK and Ireland update For personal use only In market sales in the UK and Ireland grew 167% in H2FY17. There are 56 hospital formulary approvals. All 56 hospitals are ordering on a regular basis. Penthrox has been sold into 122 Hospitals, clinics and ambulance services in the UK and Irelan
Slide 6: Penthrox France update
Penthrox® France update For personal use only We are delighted by our partner’s progress in France. In market sales in France are growing quickly. In summary: • The target is 350 hospitals to approve Penthrox in France. • 250 formulary applications have already been submitted. • 99 formularies have
Slide 7: Regulatory approval for Penthrox in the rest of Europe
Penthrox® Regulatory approval for Penthrox in the rest of Europe For personal use only We are ahead of our timeline for Penthrox to be approved in another 22 European countries. Sales are expected during H2FY18. We expect Regulatory Approvals for an additional 15 countries during 2018. 7
Slide 8: Penthrox Australia and New Zealand
Penthrox® Australia and New Zealand For personal use only Sales of Penthrox to Ambulance in Australia remain strong. Sales of Penthrox to Hospitals grew 20%. Sales of Penthrox to GP’s grew 21%. Sales of Penthrox to NZ Ambulance grew 593% as a result of all NZ Ambulances adopting Penthrox as first li
Slide 9: Penthrox USA
Penthrox® USA For personal use only Work on getting Penthrox approved in the USA is progressing well. We are on track to submit our IND in the next six months. After discussions with the FDA we will request Penthrox be granted “fast track” status by the FDA. We are very encouraged by our recent FDA
Slide 10: Penthrox clinical program for USA
Future of Penthrox® Penthrox® clinical program for USA For personal use only 2017 2018 2019 2020 FDA Approval IND Toxicology: Repeat dose and dose ranging - 2 by 28 Day Repeat Dose Healthy Volunteer Trial studies - General validation and Additional Phase III to support assay studies to support exist
Slide 11: Global growth plans
Future of Penthrox® Global growth plans 2010 For personal use only Pre 2000 2015 2020 2021 - 2022 Planned 2019- 2020 Launch: ▪ Malaysia Planned 2017 & 2018 ▪ Thailand Launch: ▪ Philippians Planned Launch: ▪ Brazil 2016 ▪ Canada ▪ Indonesia ▪ Columbia 2014 Launched: ▪ Germany ▪ Chile Launched: ▪ Irel
Slide 12: Clinical development program
Future of Penthrox® Clinical development program For personal use only Additional clinical trials and studies are planned for FY18 (and beyond) which will broaden the indications for use of Penthrox®. Our longer term ambition is to extend the use of Penthrox® into: • Acute Pain / Minor Surgical Proc
Slide 13: Clinical development program
Future of Penthrox® Clinical development program For personal use only A summary of clinical trials and studies underway (including in planning stage) which are designed to gain regulatory approvals around the world and extend the approved “indications of use” for Penthrox: • Paediatric study for Pe
Slide 14: New manufacturing technology
Future of Penthrox ® New manufacturing technology For personal use only Our new manufacturing facility has been completed on time and on budget. TGA is scheduled to return and audit the facility during September. We expect to be fully GMP compliant by the end of 2017. The new facility will deliver a
Slide 15: New manufacturing technology
Future of MVP New manufacturing technology For personal use only Our Process Development Project (PDP) with the CSIRO is progressing very well. Our ambition is to develop new manufacturing technologies that will deliver cost saving, improved quality, consistency and safety standards for existing and
Slide 16: New manufacturing technology
Future of MVP New manufacturing technology For personal use only We have successfully invented a process to manufacture a small molecule pharmaceutical where the raw material is usually purchased at Reaction Step 4. We are investigating ways we can make the raw material at Reaction Step 4 using our
Slide 17: Intellectual Property
Future of MVP Intellectual Property For personal use only MVP is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. MVP has filed and is managing the following patents and trademarks: • 6 Penthrox Inhaler patents; • 1 manufacturing paten
Slide 18: Penthrox Outlook
Penthrox® Outlook For personal use only MVP’s ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months+ we expect to: 1. obtain approval to sell Penthrox in 37 countries throughout Europe and in a
Slide 19: Respiratory and Medical Devices
For personal use only Respiratory and Medical Devices 19
Slide 20: MVP Medical Respiratory Division
MVP Medical Respiratory Division For personal use only RESPIRATORY DEVICE p 50% TOTAL GROSS SALES $ 7,000,000 Sales of Respiratory Devices across the world grew 50% 6,000,000 5,000,000 Sales of Respiratory Devices in the USA grew 353% 4,000,000 3,000,000 We now have almost 11,000 pharmacies availabl
Slide 21: Respiratory Devices sold in countries
Respiratory Devices Sold in 20 countries For personal use only Netherlands Switzerland Austria Germany UK Belgium Canada Greece Italy Cyprus USA Spain Korea Portugal Hong Kong Singapore Malaysia UAE KSA New Zealand Australia 21
Slide 22: Respiratory Devices USA
Respiratory Devices USA For personal use only We have access to 11,000 pharmacies in the USA We are core range for Walmart, Sam’s, Kmart and others There are 67,000 pharmacies in the USA The response to our product offering in the USA has been excellent We are working on additional pharmacy chain de
Slide 23: Respiratory Devices Intellectual Property
Respiratory Devices Intellectual Property For personal use only MVP is protecting its future by generating intellectual property from its new range of respiratory devices. MVP has filed a number of global patents. MVP has filed international Trade Marks and Registered Designs in more than 20 countri
Slide 24: Respiratory Devices Outlook
Respiratory Devices Outlook For personal use only MVP’s ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 20 countries. Over the next 12 months we expect to: 1. obtain additional partnership deals in the USA an
Slide 25: MVP Corporate
For personal use only MVP Corporate 25
Slide 26: Financial Summary
Financial Summary For personal use only GROSS REVENUE p 22% INCREASE TO $18.9M During the year MVP: $ 20,000,000 • 17,500,000 Delivered gross sales of $18.9m up 22% 15,000,000 12,500,000 • Delivered Net Profit after tax of $1.82million up 16% 10,000,000 FY15 FY16 FY17 • Incurred $550K of “one off” e
Slide 27: Financial Summary
Financial Summary For personal use only MVP: • Recently secured a Debt Funding facility of $11m which will be used to fund future development projects • Received $7.3m in upfront and milestone payments from partners • Invested: • $4.3m into the new manufacturing facility, • $4.3m into clinical trial
Slide 28: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3yr) Current Stock Price 0.010 (0.19%) 5.14 16 Aug, 3:26pm Day High 5.150 Day Low 5.090 Open 5.150 Prev. Close 5.150 Avg. Volume 13,332 52 Wk. High 5.990 (16 Aug 2016) 52 Wk. Low 4.120 (6 Dec 2016) Mkt. Cap 300.18 (Mil)
Slide 29: MVP Corporate Overview
MVP Corporate Overview For personal use only David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing Director A Medical Co
Slide 30: MVP Global Strategy
MVP Global Strategy New and revised For personal use only materials and process (lowest cost producer and New significant IP) Business Partners Product innovation (world’s best manufacturing processes and delivery devices resulting in significant IP) Clinical trials (Commercial clinical studies to s
Slide 31: Contact Details
Contact Details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com 31
Slide 32: For personal use only
For personal use only 0817 Medical Developments International
Medical Developments International — Investor Presentation (August 2017) on 6ix